메뉴 건너뛰기




Volumn 78, Issue 10, 2014, Pages 2512-2515

Differences between Rosuvastatin and Atorvastatin in lipid-lowering action and effect on glucose metabolism in Japanese hypercholesterolemic patients with concurrent diabetes - Lipid-lowering with highly potent statins in hyperlipidemia with type 2 diabetes patients (LISTEN) study-

Author keywords

Hypercholesterolemia; Statins; Type 2 diabetes mellitus

Indexed keywords

ATORVASTATIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; FLUOROBENZENE; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; SULFONAMIDE;

EID: 84908250590     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-14-0810     Document Type: Article
Times cited : (25)

References (15)
  • 1
    • 84858964598 scopus 로고    scopus 로고
    • Reverse vessel remodeling but not coronary plaque regression could predict future cardiovascular events in ACS patients with intensive statin therapy: The extended JAPAN-ACS study
    • Miyauchi K, Daida H, Morimoto T, Hiro T, Kimura T, Nakagawa Y, et al. Reverse vessel remodeling but not coronary plaque regression could predict future cardiovascular events in ACS patients with intensive statin therapy: The extended JAPAN-ACS study. Circ J 2012; 76: 825-832.
    • (2012) Circ J , vol.76 , pp. 825-832
    • Miyauchi, K.1    Daida, H.2    Morimoto, T.3    Hiro, T.4    Kimura, T.5    Nakagawa, Y.6
  • 2
    • 84861594738 scopus 로고    scopus 로고
    • Intensity of statin therapy, achieved low-density lipoprotein cholesterol levels and cardiovascular outcomes in Japanese patients after coronary revascularization: Perspectives from the CREDO-Kyoto registry cohort-2
    • Natsuaki M, Furukawa Y, Morimoto T, Nakagawa Y, Ono K, Kaburagi S, et al. Intensity of statin therapy, achieved low-density lipoprotein cholesterol levels and cardiovascular outcomes in Japanese patients after coronary revascularization: Perspectives from the CREDO-Kyoto registry cohort-2. Circ J 2012; 76: 1369-1379.
    • (2012) Circ J , vol.76 , pp. 1369-1379
    • Natsuaki, M.1    Furukawa, Y.2    Morimoto, T.3    Nakagawa, Y.4    Ono, K.5    Kaburagi, S.6
  • 3
    • 0037840242 scopus 로고    scopus 로고
    • Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial
    • Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet 2003; 361: 2005-2016.
    • (2003) Lancet , vol.361 , pp. 2005-2016
    • Collins, R.1    Armitage, J.2    Parish, S.3    Sleigh, P.4    Peto, R.5
  • 4
    • 4344683381 scopus 로고    scopus 로고
    • Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial
    • Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-696.
    • (2004) Lancet , vol.364 , pp. 685-696
    • Colhoun, H.M.1    Betteridge, D.J.2    Durrington, P.N.3    Hitman, G.A.4    Neil, H.A.5    Livingstone, S.J.6
  • 5
    • 33746431474 scopus 로고    scopus 로고
    • Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN)
    • Knopp RH, d’Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 2006; 29: 1478-1485.
    • (2006) Diabetes Care , vol.29 , pp. 1478-1485
    • Knopp, R.H.1    D’emden, M.2    Smilde, J.G.3    Pocock, S.J.4
  • 6
    • 56749106312 scopus 로고    scopus 로고
    • Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein
    • Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-2207.
    • (2008) N Engl J Med , vol.359 , pp. 2195-2207
    • Ridker, P.M.1    Danielson, E.2    Fonseca, F.A.3    Genest, J.4    Gotto, A.M.5    Kastelein, J.J.6
  • 7
    • 84878773567 scopus 로고    scopus 로고
    • Risk of incident diabetes among patients treated with statins: Population based study
    • Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM. Risk of incident diabetes among patients treated with statins: Population based study. BMJ 2013; 346: 2610.
    • (2013) BMJ , vol.346 , pp. 2610
    • Carter, A.A.1    Gomes, T.2    Camacho, X.3    Juurlink, D.N.4    Shah, B.R.5    Mamdani, M.M.6
  • 8
    • 79959428660 scopus 로고    scopus 로고
    • Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: A meta-analysis
    • Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: A meta-analysis. JAMA 2011; 305: 2556-2564.
    • (2011) JAMA , vol.305 , pp. 2556-2564
    • Preiss, D.1    Seshasai, S.R.2    Welsh, P.3    Murphy, S.A.4    Ho, J.E.5    Waters, D.D.6
  • 9
    • 77549087054 scopus 로고    scopus 로고
    • Statins and risk of incident diabetes: A collaborative metaanalysis of randomised statin trials
    • Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: A collaborative metaanalysis of randomised statin trials. Lancet 2010; 375: 735-742.
    • (2010) Lancet , vol.375 , pp. 735-742
    • Sattar, N.1    Preiss, D.2    Murray, H.M.3    Welsh, P.4    Buckley, B.M.5    De Craen, A.J.6
  • 10
    • 84901704225 scopus 로고    scopus 로고
    • Higher potency statins and the risk of new diabetes: Multicentre, observational study of administrative databases
    • Dormuth CR, Filion KB, Paterson JM, James MT, Teare GF, Raymond CB, et al. Higher potency statins and the risk of new diabetes: Multicentre, observational study of administrative databases. BMJ 2014; 348: 3244.
    • (2014) BMJ , vol.348 , pp. 3244
    • Dormuth, C.R.1    Filion, K.B.2    Paterson, J.M.3    James, M.T.4    Teare, G.F.5    Raymond, C.B.6
  • 11
    • 84864861863 scopus 로고    scopus 로고
    • Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: An analysis from the JUPITER trial
    • Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: An analysis from the JUPITER trial. Lancet 2012; 380: 565-571.
    • (2012) Lancet , vol.380 , pp. 565-571
    • Ridker, P.M.1    Pradhan, A.2    Macfadyen, J.G.3    Libby, P.4    Glynn, R.J.5
  • 12
    • 84897970506 scopus 로고    scopus 로고
    • ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
    • Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129(Suppl 2): S1-S45.
    • (2013) Circulation 2014; 129(Suppl , vol.2 , pp. S1-S45
    • Stone, N.J.1    Robinson, J.G.2    Lichtenstein, A.H.3    Bairey Merz, C.N.4    Blum, C.B.5    Eckel, R.H.6
  • 13
    • 33846414720 scopus 로고    scopus 로고
    • Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: Executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
    • Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: Executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28: 88-136.
    • (2007) Eur Heart J , vol.28 , pp. 88-136
    • Rydén, L.1    Standl, E.2    Bartnik, M.3    Van Den Berghe, G.4    Betteridge, J.5    De Boer, M.J.6
  • 14
    • 44349104255 scopus 로고    scopus 로고
    • Effects of atorvastatin and pravastatin on signal transduction related to glucose uptake in 3T3L1 adipocytes
    • Takaguri A, Satoh K, Itagaki M, Tokumitsu Y, Ichihara K. Effects of atorvastatin and pravastatin on signal transduction related to glucose uptake in 3T3L1 adipocytes. J Pharmacol Sci 2008; 107: 80-89.
    • (2008) J Pharmacol Sci , vol.107 , pp. 80-89
    • Takaguri, A.1    Satoh, K.2    Itagaki, M.3    Tokumitsu, Y.4    Ichihara, K.5
  • 15
    • 34548476976 scopus 로고    scopus 로고
    • Usefulness of hydrophilic vs lipophilic statins after acute myocardial infarction: Subanalysis of MUSASHI-AMI
    • Sakamoto T, Kojima S, Ogawa H, Shimomura H, Kimura K, Ogata Y, et al. Usefulness of hydrophilic vs lipophilic statins after acute myocardial infarction: Subanalysis of MUSASHI-AMI. Circ J 2007; 71: 1348-1353.
    • (2007) Circ J , vol.71 , pp. 1348-1353
    • Sakamoto, T.1    Kojima, S.2    Ogawa, H.3    Shimomura, H.4    Kimura, K.5    Ogata, Y.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.